MedTrace Logo

Study of VX-770 on Desipramine

NCT01153542 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-12-09

No results posted yet for this study

Summary

The objective of this study is to evaluate the effects of VX-770 on Desipramine

Conditions

  • In Development for Cystic Fibrosis

Interventions

DRUG

VX-770

In period 1, subjects will receive a single oral dose of desipramine on Day 1.

DRUG

VX-770

In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.

Sponsors & Collaborators

Principal Investigators

  • H. Frank Farmer, MD · Covance CRU, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153542 on ClinicalTrials.gov